Interviews

In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.

Patrick Wen, MD, looks at how emerging evidence has shown promise for targeting mutations in patients with glioblastomas when it was once believed these therapies may not work for these patients.

In an interview with Targeted Oncology, Christopher Chambers, MD, discussed how primary care physicians are involved with the diagnosis of cancer and the challenges faced with early detection.

Robert J. Soiffer, MD, discusses the role of transplantation and relapse after transplant for patients with cancer.

In an interview with Targeted Oncology, Hitomi Hosoya, MD, discussed the potential use of ctDNA in the myeloma space, including its ability to sequence BCMA-targeted therapies and reduce the need for bone marrow exams.

In an interview with Targeted Oncology, Matthew Manning, MD, FASTRO, discussed the many radiation oncology tasks that have been improved with AI and its prospective utility in cancer diagnosis and treatment decisions.

Nitin Jain, MD, discusses future improvements he anticipates for autologous and allogeneic chimeric antigen receptor T-cell therapies for B-cell acute lymphoblastic leukemia and other hematologic malignancies.

Yuri E. Nikiforov, MD, PhD, discusses the reclassification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, which has significantly influenced the thyroid cancer space.

In an interview with Targeted Oncology, Yuri E. Nikiforov, MD, PhD, discussed what led to the reclassification of NIFTP and the incidence of thyroid cancer in patients.

Anna Jo Bodurtha Smith, MD, discusses background on her research regarding insurance-mediated disparities in gynecologic oncology.

Casey M. Cosgrove, MD, discusses research exploring precision medicine concepts for endometrial cancer treatment.

Casey M. Cosgrove, MD, discusses biomarker-guided treatment for endometrial cancer.

Lori Leslie, MD, discusses ongoing clinical trials that are exploring chimeric antigen receptor T-cell therapy for the treatment of B-cell malignancies.

In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.

Lori Leslie, MD, describes the cohorts of the phase 2 ZUMA-2 study and discusses the potential impact of brexucabtagene autoleucel in the mantle cell lymphoma landscape.

Jashodeep Datta, MD, explains KRAS and TP53 co-alterations in patients with pancreatic cancer.

Thomas G. Martin, MD, discusses the mechanism of action of bispecific T-cell engagers including teclistamab-cqyv in patients with relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, Brian A. Jonas, MD took a close look at the precision medicine landscape for AML and discussed key biomarkers and research needs for the future.

Brian A. Jonas, MD, PhD, discusses novel biomarkers being explored in acute myeloid leukemia, including e-selectin, which Jonas believes is very promising.

In an interview with Targeted Oncology, Matthew Matasar, MD, breaks down what he sees as some of the most exciting data in the field of treatment for patients with lymphoma and what the future may hold for this patient population.

Charles Geyer, MD, discusses the potential impact of adjuvant olaparib on the treatment landscape for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

In an interview with Targeted Oncology, Zahra Mahmoudjafari, PharmD, BCOP, discussed the post hoc analysis from the REACH2 trial and highlighted the key takeaways.

Jennifer R. Brown, MD, PhD, discusses what potential advancements are bringing excitement into the chronic lymphocytic leukemia space.

Yann-Alexandre Vano, MD, explains the methods and design of the phase 2 BIONIKK trial for patients with renal cell carcinoma.

Zev A. Wainberg, MD, discusses recent findings from the NAPOLI 3 trial which were presented at the 2023 Gastrointestinal Cancers Symposium.

Neeta Somaiah, MD, discusses new and upcoming targeted therapies for sarcomas at the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium.

Jason Luke, MD, discussed the role played by the combination of nivolumab plus relatlimab in patients with advanced melanoma.

Mitchell Smith, MD, PhD, discusses the updated results of the phase 2 ECOG-ACRIN E1411 trial of patients with previously untreated mantle cell lymphoma.